HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
ETFs
Mutual Funds
Options
RSS Feed
Profit from the Pros
Subscription Services
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


MYL: MYLAN INC - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

MYLAN INC (NASD)
MYL 22.44 0.68 (3.13%) Vol.  5,039,636 16:00 ET

Zacks Rank: 3 - Hold


Day Low - High 22.02 - 22.47
52wk Low - High 15.49 - 25.46
Avg Volume 5,231,031
Industry MED-GENERIC DRG
Market Cap 9.28 B
Div - Yield 0.00 - 0.00
PE (forward) 9.09
PEG Ratio .85
Current Year Est. 2.39
EPS Last Year 1.96
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.05%
# 2Buy18.22%
# 3Hold9.31%
# 4Sell3.69%
# 5Strong Sell1.45%
S&P5008.92%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
down 3 - Hold
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 01/23/2012
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
MYLAN INC MYL 3
AKORN INC AKRX 1
HI TECH PHARMA HITK 1
PAR PHARMA COS PRX 2
Top Peer Analysis Zacks Premium
See all MED-GENERIC DRG Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.92
ABR (Last Week) 1.92
# of Recs in ABR 18
Average Target Price 25.53
Rank in Industry 6 out of 11
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate MYL?
Buy
Sell
Find out what the Zacks Community
thinks of MYL at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




 
ZACKS COMMENTARY FOR MYL
Zacks Blog: Zacks Bull and Bear of the Day Highlights: Mylan, JAKKS Pacific, Chevron, BP plc and ExxonMobil
Jan 30, 2012
Bull of the Day: Mylan, Inc. (MYL)
Jan 30, 2012
Zacks Blog: Mylan Inc Enters Oversold Territory
Jan 25, 2012
Zacks Blog: Zacks Bull and Bear of the Day Highlights: DaVita, Hhgregg, Mylan, Teva Pharmaceutical and Novartis
Jan 25, 2012
Zacks Blog: Medicines Co. Settles with APP
Jan 24, 2012
Zacks Blog: Mylan Outperforms as Generics Rule
Jan 24, 2012
Zacks Equity Research: Report for MYL
Jan 23, 2012
Zacks Blog: Shire, Prasco Ink Deal
Jan 16, 2012
More Zacks Commentary
NEWS
Mylan (MYL) Approaches New Upside Target of $22.23
Feb 03, 2012
Mylan Inc awarded tentative FDA approval for generic cardiovascular drug Lipitor
Feb 03, 2012
Mylan (MYL) Approaches New Upside Target of $22.23 - Story Title - Comtex
Feb 03, 2012
Mylan Inc awarded tentative FDA approval for generic cardiovascular drug Lipitor - Story Title - Comtex
Feb 03, 2012
Hot Stock Research for Texas Instruments, Mylan, and NetApp
Feb 02, 2012
Mylan Receives Tentative FDA Approval for Generic Version of LipitorA?
Feb 02, 2012
Hot Stock Research for Texas Instruments, Mylan, and NetApp - Story Title - Comtex
Feb 02, 2012
Mylan Receives Tentative FDA Approval for Generic Version of Lipitor - Benzinga
Feb 02, 2012
More News
EARNINGS ESTIMATES
  This Quarter
12/2011
Next Quarter
03/2012
This Year
12/2011
Next Year
12/2012
Average Estimate 0.50 0.54 2.00 2.39
Number of Estimates 17 9 19 18
Low Estimates 0.48 0.53 1.95 2.28
High Estimate 0.52 0.56 2.03 2.52
Year Ago EPS 0.45 0.44 1.61 2.00
EPS Growth 10.33% 23.48% 24.42% 19.53%

More Estimates

COMPANY DESCRIPTION
Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

Full Company Report
FINANCIALS
EPS TTM 1.96
Sales 5450.52
Net Income 427.17
Price/Earnings 11.1
Price/Book 2.65
Price/Cash Flow 8.38
Price/Sales 1.54


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research